Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:ALIM
Date4/2010
Raised
Post IPO Valuation

General Information

Websitealimerasciences.com
Twitter@AlimeraSciences
CategoryBioTech
Phone678.990.5740
Employees
Founded2003
DescriptionBiopharmaceutical

Offices

Alpharetta, USA
6120 Windward Parkway
Suite 290
Alpharetta, GA, 30005
USA

People

CFO
COO
President and CEO
senior VP of sales and marketing
Board of Directors
Board of Directors
Board of Directors & Chair, Audit Committee
Director
Show All People

Funding

TOTAL $144M
FUNDING TOTAL $66.8M
Series B, 11/2005
Venrock
Scale Venture Partners
Domain Associates
Intersouth Partners
Polaris Partners
$31.8M
Series C, 3/2008
$30M
Series C, 10/2009
Polaris Partners
Intersouth Partners
Venrock
Domain Associates
Scale Venture Partners
$5M
POST IPO FUNDING TOTAL $77.5M
Post IPO Equity, 10/2012
$40M
Post IPO Equity, 1/2014
$37.5M

Tags

Alimera Sciences

Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.

Recent Milestones

Videos

Screenshots

Products

Iluvien

Add some content to this product

Stock Price

Sources

  1. Alimera Sciences Secures $31.8 Million in Series B Financing (gabio.org) [edit]
  2. Alimera Sciences Closes $30 Million In Series C Financing, Increasing Stake In Medidur™ FA (alimerasciences.com) [edit]
  3. Alimera Sciences, Inc.: Series C $5M (onbiovc.com) [edit]
  4. Publicly Traded Alimera Sciences Raises $40M From New and Returning VCs (pevc.dowjones.com) [edit]
  5. Alimera Sciences (ALIM) Snags $37.5 Million Private Placement (biospace.com) [edit]
Edit This Page
Last Edited 2/18/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy